1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
(
- Contribution to journal › Article
-
Mark
Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
(
- Contribution to journal › Article
- 2016
-
Mark
Promoter Methylation of PTEN is a Significant Prognostic Factor in Melanoma Survival.
(
- Contribution to journal › Article
- 2015
-
Mark
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
(
- Contribution to journal › Article
-
Mark
MITF Modulates Therapeutic Resistance through EGFR Signaling.
(
- Contribution to journal › Article
-
Mark
BAP1 Plays a Survival Role in Cutaneous Melanoma.
(
- Contribution to journal › Article
- 2014
-
Mark
Primary Melanoma Tumors from CDKN2A Mutation Carriers do not Belong to a Distinct Molecular Subclass.
(
- Contribution to journal › Article
-
Mark
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
(
- Contribution to journal › Article
-
Mark
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
(
- Contribution to journal › Letter
- 2010
-
Mark
Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
(
- Contribution to journal › Article